Nothing Special   »   [go: up one dir, main page]

DK3013855T3 - Mutante faktor VIII-sammensætninger og fremgangsmåder - Google Patents

Mutante faktor VIII-sammensætninger og fremgangsmåder Download PDF

Info

Publication number
DK3013855T3
DK3013855T3 DK14817835.3T DK14817835T DK3013855T3 DK 3013855 T3 DK3013855 T3 DK 3013855T3 DK 14817835 T DK14817835 T DK 14817835T DK 3013855 T3 DK3013855 T3 DK 3013855T3
Authority
DK
Denmark
Prior art keywords
methods
factor viii
mutant factor
viii compositions
compositions
Prior art date
Application number
DK14817835.3T
Other languages
English (en)
Inventor
Wenjing Cao
Biao Dong
Original Assignee
Xiao Weidong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiao Weidong filed Critical Xiao Weidong
Application granted granted Critical
Publication of DK3013855T3 publication Critical patent/DK3013855T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK14817835.3T 2013-06-24 2014-06-24 Mutante faktor VIII-sammensætninger og fremgangsmåder DK3013855T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361838867P 2013-06-24 2013-06-24
PCT/US2014/043777 WO2014209942A1 (en) 2013-06-24 2014-06-24 Mutant factor viii compositions and methods

Publications (1)

Publication Number Publication Date
DK3013855T3 true DK3013855T3 (da) 2021-01-11

Family

ID=52142603

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14817835.3T DK3013855T3 (da) 2013-06-24 2014-06-24 Mutante faktor VIII-sammensætninger og fremgangsmåder

Country Status (14)

Country Link
US (3) US20160102133A1 (da)
EP (2) EP3013855B1 (da)
CN (1) CN105431451B (da)
CY (1) CY1124110T1 (da)
DK (1) DK3013855T3 (da)
ES (1) ES2837475T3 (da)
HR (1) HRP20210031T1 (da)
HU (1) HUE052074T2 (da)
LT (1) LT3013855T (da)
PL (1) PL3013855T3 (da)
PT (1) PT3013855T (da)
RS (1) RS61305B1 (da)
SI (1) SI3013855T1 (da)
WO (1) WO2014209942A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6800863B2 (ja) * 2015-02-06 2020-12-16 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 最適化されたヒト凝固第ｖｉｉｉ因子遺伝子発現カセットおよびその使用
TW202302627A (zh) 2015-11-13 2023-01-16 日商武田藥品工業股份有限公司 用於ａ型血友病基因治療之編碼表現增加之重組ｆｖｉｉｉ變異體之病毒載體
WO2019210270A2 (en) * 2018-04-27 2019-10-31 Seattle Children's Hospital D/B/A Seattle Children's Research Institute In vivo gene therapy using delivery of a lentiviral gene construct
EP3823985A1 (en) 2018-07-16 2021-05-26 Baxalta Incorporated Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
WO2022211791A1 (en) * 2021-03-30 2022-10-06 AAVnerGene Inc. Modified plasma clotting factor viii and method of use thereof
US11795207B2 (en) 2021-03-30 2023-10-24 AAVnerGene Inc. Modified plasma clotting factor VIII and method of use thereof
WO2023092864A1 (en) * 2021-11-25 2023-06-01 Sichuan Real&Best Biotech Co., Ltd. Engineered human fviii with enhanced secretion ability and clotting activity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US20040092442A1 (en) 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
CA2348382C (en) 1998-11-10 2013-09-17 The University Of North Carolina At Chapel Hill Chimeric parvovirus vectors and methods of making and administering the same
EP1038959A1 (en) 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Factor VIII without B-domain, comprising one or more insertions of a truncated intron I of factor IX
AU2001269723B9 (en) 2000-06-01 2006-11-16 University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
KR100638184B1 (ko) 2000-09-19 2006-10-26 에모리 유니버시티 변형된 인자 ⅷ
EP1233064A1 (en) 2001-02-09 2002-08-21 Aventis Behring Gesellschaft mit beschränkter Haftung Modified factor VIII cDNA and its use for the production of factor VIII
DE60230456D1 (de) 2001-10-05 2009-01-29 Expression Therapeutics Llc Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
EP1424344A1 (en) 2002-11-29 2004-06-02 Aventis Behring Gesellschaft mit beschränkter Haftung Modified cDNA factor VIII and its derivates
US7211559B2 (en) * 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
ATE463572T1 (de) * 2003-12-03 2010-04-15 Univ Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
BRPI0913374A2 (pt) * 2008-06-04 2015-11-24 Bayer Healthcare Llc muteínas fviii para tratamento de doença de von willebrand
EP2593130A2 (en) 2010-07-15 2013-05-22 Novo Nordisk A/S Stabilized factor viii variants
US8637448B2 (en) * 2010-09-14 2014-01-28 University Of Rochester Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface

Also Published As

Publication number Publication date
SI3013855T1 (sl) 2021-06-30
US20160102133A1 (en) 2016-04-14
EP3013855A4 (en) 2017-12-13
EP3904376A1 (en) 2021-11-03
LT3013855T (lt) 2021-01-25
CN105431451A (zh) 2016-03-23
RS61305B1 (sr) 2021-02-26
EP3013855A1 (en) 2016-05-04
HRP20210031T1 (hr) 2021-05-14
EP3904376B1 (en) 2024-11-13
EP3013855B1 (en) 2020-10-14
PT3013855T (pt) 2021-01-13
ES2837475T3 (es) 2021-06-30
US20190177399A1 (en) 2019-06-13
US20220144919A1 (en) 2022-05-12
CY1124110T1 (el) 2022-05-27
WO2014209942A1 (en) 2014-12-31
PL3013855T3 (pl) 2021-04-19
CN105431451B (zh) 2024-08-23
US11261234B2 (en) 2022-03-01
HUE052074T2 (hu) 2021-04-28

Similar Documents

Publication Publication Date Title
IL273205A (en) Preparations and methods
IL269461B (en) Cytidine-5-carboxamide modified nucleotide preparations and related methods
HK1218837A1 (zh) 組合物和方法
HK1218560A1 (zh) 組成與方法
GB2521022B (en) Compositions and methods
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK3043784T3 (da) Arylethere og anvendelser deraf
DK3494985T3 (da) Vaccinesammensætning omfattende mutant calreticulin
GB201308072D0 (en) Compositions and methods
DK3018183T3 (da) Halogenolefinbaseret sammensætning og anvendelse deraf
IL245470B (en) Methods and preparations for delayed immunotherapy
DK3077467T3 (da) Sikkativsammensætning og anvendelse deraf
DK2962100T3 (da) Tuberkulosebiomarkører og anvendelser deraf
IL280725B (en) Neisseria meningitidis preparations and methods of their use
IL246518A0 (en) The compositions, including nanosheets, and methods to prevent friction wear and lubrication
DK3013855T3 (da) Mutante faktor VIII-sammensætninger og fremgangsmåder
DK3058936T3 (da) Peptidsammensætning og anvendelser deraf
GB201305813D0 (en) Compositions and methods
EP2964610A4 (en) VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF
DK3223846T3 (da) Adjuvanssammensætninger og tilhørende fremgangsmåder
DK3068428T3 (da) Annexin-ii-variant-sammensætninger og fremgangsmåder
DK3191080T3 (da) Parenterale sammensætninger og anvendelser deraf
GB201322617D0 (en) Methods and compositions
GB201312393D0 (en) Compositions and Methods
EP3003323A4 (en) POLYSACCARIDE COMPOSITIONS AND CORRESPONDING METHODS